• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Cuba encouraged by early trials of homegrown COVID-19 vaccine

firstwordpharmaJune 21, 2021

Tag: Cuba , COVID-19 , Vaccine

Cuba's state-run biopharmaceutical corporation BioCubaFarma said preliminary data from late phase trials showed that the Soberana 2 vaccine candidate for COVID-19 had 62% efficacy with just two of its three doses, as reported Fidelity.

Cuba encouraged by early trials of homegrown COVID-19 vaccine

"In a few weeks we should have the results for the efficacy with three doses which we expect will be superior," said Vicente Vérez, director of the Finlay Vaccine Institute, which developed Soberana 2.

Several countries from have expressed an interest in buying Cuba's vaccines, and Iran started producing Soberana 2 earlier this year as part of late-phase trials.

Previous:Israeli scientists find promising target for breast cancer and other cancer therapeutics

Next:China's Sinopharm COVID-19 vaccines arrive in Thailand

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Cuba encouraged by early trials of homegrown COVID-19 vaccine | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Flu Vaccine by Hualan Bio

Flu Vaccine by Hualan Bio
Hangzhou economic development zone no. 6 street 5 b03 high-tech incubator building 1, 452

Hangzhou economic development zone no. 6 street 5 b03 high-tech incubator building 1, 452
High-standard Influenza Vaccine (Split virion), inactivated

High-standard Influenza Vaccine (Split virion), inactivated
Hualan Biological Influenza Vaccine

Hualan Biological Influenza Vaccine
Trivalent Influenza Vaccine

Trivalent Influenza Vaccine
Real Time Multiplex RT-PCR Kit (for COVID-19)

Real Time Multiplex RT-PCR Kit (for COVID-19)
Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard

Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard
Swine Vaccine Series

Swine Vaccine Series
CO2Incubator

CO2Incubator
Hualan flu vaccine

Hualan flu vaccine

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service